Table of Content

1. Nanoparticles – New Era of Drug Delivery Methodology
1.1 Targeted Drug Delivery by Nanoparticles
1.2 Enhancing the Therapeutics Efficacy


2. Need for Nanoparticle Drug Delivery
2.1 Limitations of Traditional Drug Delivery Techniques
2.2 Rising Demand for Better Targeted Drug Delivery Techniques in the Oncology
Segment
2.3 Better Therapeutic Outcome than Conventional Drug Delivery Methods


3. Importance of Nanoparticle Drug Delivery in Cancer Therapy
3.1 Wide Application of Nanoparticles in Cancer Therapy
3.2 Mechanisms of Nanoparticle Internalization in Cancer Cells for Imaging &
Therapy
3.3 Role of Nanoparticles in Better Diagnosis of Cancer


4. Nanoparticle Drug Delivery Techniques
4.1 Nanocrystals
4.2 Liposomes
4.3 Dendrimers
4.4 Micelle Based Drug Delivery
4.5 Polymeric Nanoparticles
4.6 Metal Based Nanoparticles (Gold, iron oxide)
4.7 Fullerenes & Carbon Nanotube
4.8 Quantum Dots Delivery


5. Global Nanoparticle Drug Market Overview
5.1 Current Market Scenario
5.2 Future Market Opportunity

6. Global Nanoparticle Drug Market Regional Analysis
6.1 US
6.2 Europe
6.3 China
6.4 Japan
6.5 India
6.6 Taiwan
6.7 South Korea
6.8 Canada


7. Global Nanoparticle Drug Market by Indication
7.1 Oncology
7.2 Autoimmune Diseases
7.3 Iron Deficiency Anemia
7.4 Neurological Disorders


8. Cancer Nanoparticle Therapeutics - Price & Dosage Insight
8.1 Liposomal Doxorubicin
8.2 Paclitaxel Protein-Bound
8.3 Megace ES (Enhanced Stability)
8.4 Vyxeos (Cytarabine and Daunorubicin)
8.5 Marqibo
8.6 Oncaspar (Pegaspargase)
8.7 Onivyde
8.8 Cynviloq
8.9 Hensify
8.10 Paclical
8.11 Mepact
8.12 Lipusu
8.13 Eligard


9. Anemia Nanoparticle Therapeutics - Price & Dosage Insight
9.1 Ferumoxytol (Feraheme)
9.2 Injectafer (Ferric Carboxymaltose)
9.3 Venofer
9.4 Ferrlecit
9.5 Infed
9.6 Mircera


10. Autoimmune Diseases Nanoparticle Therapeutics - Price & Dosage Insight
10.1 Copaxone (Glatiramer)
10.2 Cimzia
10.3 Plegridy (Peginterferon beta-1a)
10.4 Krystexxa (Pegloticase)
10.5 Zilretta (Triamcinolone Acetonide)


11. Neurological Disorders Nanoparticle Therapeutics - Price & Dosage Insight
11.1 Onpattro (Patisiran)
11.2 Visudyne (Verteporfin)


12. Price & Dosage Analysis of Commercially Available Other Nanoparticle Therapeutics
12.1 Amphotericin B Liposomal
12.2 Rapamune
12.3 Emend (Aprepitant Nanocrystal)
12.4 Triglide – Nanocrystal Version of Tricor
12.5 Neulasta
12.6 Ritalin (Methylphenidate)
12.7 Renagel (Sevelamer)
12.8 Abelcet
12.9 Somavert (Pegvisomant)
12.10 Rebinyn/Refixia
12.11 Invega (Paliperidone)


13. Global Nanoparticle Therapeutics Approved Drus – Sales Analysis & Forecast Till 2028
13.1 Ambisome
13.2 Abraxane
13.3 Vyxeos
13.4 Onpattro
13.5 Neulasta
13.6 Somavert
13.7 Zilretta
13.8 Copaxone
13.9 Mircera
13.10 Injectafer
13.11 Venofer
13.12 Onivyde
13.13 Cimzia
13.14 Plegridy
13.15 Krystexxa


14. Global Nanoparticle Drug Clinical Trial Insights
14.1 By Status
14.2 By Phase
14.3 By Region


15. Global Nanoparticle Drugs Clinical Pipeline Insight By Phase, Company & Indication
15.1 Research
15.2 Preclinical
15.3 Clinical
15.4 Phase-I
15.5 Phase-I/II
15.6 Phase-II
15.7 Phase-II/III
15.8 Phase-III
15.9 Registered


16. Marketed Nanoparticles Drug Clinical Insight


17. Nanoparticle Drug Delivery Market Dynamics
17.1 Driving Factors of Nanoparticle Drug Delivery Market
17.2 Challenging Aspects of Nanoparticle Drug Delivery Segment


18. Competitive Landscape
18.1 AbbVie
18.2 Amgen
18.3 Alnylam Pharmaceuticals
18.4 Arrowhead Pharmaceuticals
18.5 BioGen
18.6 Bristol Myers Squibb
18.7 Clene Nanomedicine
18.8 Horizon Therapeutics
18.9 Merck
18.10 Nanobiotix
18.11 Nanospectra Biosciences
18.12 Novartis
18.13 Pfizer
18.14 Tandem Nano